0.12
-0.0124(-9.37%)
Currency In USD
| Previous Close | 0.13 |
| Open | 0.14 |
| Day High | 0.14 |
| Day Low | 0.11 |
| 52-Week High | 2.52 |
| 52-Week Low | 0.11 |
| Volume | 1.35M |
| Average Volume | 435,850 |
| Market Cap | 2.58M |
| PE | -0.12 |
| EPS | -1.02 |
| Moving Average 50 Days | 0.19 |
| Moving Average 200 Days | 0.37 |
| Change | -0.01 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $0.27 as of June 01, 2025 at a share price of $0.12. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $3.6 as of June 01, 2025 at a share price of $0.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Director
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Hum
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
GlobeNewswire Inc.
May 12, 2025 12:30 PM GMT
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&ASARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on deve